Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention: A report from prior to the initiation of SCIP measures

Timothy A. Damron, Zabi Wardak, Bradley Glodny, William Grant

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background and Objectives This study reviews incidence and risk factors for venous thromboembolism (VTE) in bone/soft-tissue sarcoma patients prior to the initiation of Surgical Care Improvement Program (SCIP) measures in October 2009. Methods A retrospective chart review identified 171 cases of bone (51) and soft-tissue (120) sarcoma. Data were extracted on demographics, histology, presence of metastasis at presentation, type of adjuvant therapy, and established risk factors for VTE. Risk factors and outcomes were analyzed using chi-square and logistic regression with the Fisher exact test. Results The rate of clinically diagnosed VTE was 4.1% (7/171). Only those patients undergoing chemotherapy were found to have a significantly increased risk of VTE (P=0.04). Chemical prophylaxis showed a trend toward reduction in the risk of VTE (2.4% vs. 9.1%, P=0.13). The number of individual patient prothrombotic risk factors showed a trend towards increased risk of VTE (P=0.12). Conclusions The current rate of 4.1% is at the lower end of the range of reported incidence for musculoskeletal oncology patients. Furthermore, VTE did not occur only in patients with hip/thigh sarcomas, as previously reported by some. The trend for reduced incidence with chemoprophylaxis favors prophylactic measures but requires further substantiation in larger studies.

Original languageEnglish (US)
Pages (from-to)643-647
Number of pages5
JournalJournal of Surgical Oncology
Volume103
Issue number7
DOIs
StatePublished - Jun 1 2011

Fingerprint

Venous Thromboembolism
Sarcoma
Bone and Bones
Incidence
Chemoprevention
Risk Reduction Behavior
Thigh
Hip
Histology
Cohort Studies
Logistic Models
Demography
Neoplasm Metastasis
Drug Therapy

Keywords

  • bone sarcoma
  • chemoprophylaxis
  • deep venous thrombosis
  • pulmonary embolus
  • SCIP
  • soft-tissue sarcoma
  • thromboembolic disease
  • thromboprophylaxis
  • venous thromboembolism

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention : A report from prior to the initiation of SCIP measures. / Damron, Timothy A.; Wardak, Zabi; Glodny, Bradley; Grant, William.

In: Journal of Surgical Oncology, Vol. 103, No. 7, 01.06.2011, p. 643-647.

Research output: Contribution to journalArticle

@article{8cfe2167e15446049224c1c534e167fe,
title = "Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention: A report from prior to the initiation of SCIP measures",
abstract = "Background and Objectives This study reviews incidence and risk factors for venous thromboembolism (VTE) in bone/soft-tissue sarcoma patients prior to the initiation of Surgical Care Improvement Program (SCIP) measures in October 2009. Methods A retrospective chart review identified 171 cases of bone (51) and soft-tissue (120) sarcoma. Data were extracted on demographics, histology, presence of metastasis at presentation, type of adjuvant therapy, and established risk factors for VTE. Risk factors and outcomes were analyzed using chi-square and logistic regression with the Fisher exact test. Results The rate of clinically diagnosed VTE was 4.1{\%} (7/171). Only those patients undergoing chemotherapy were found to have a significantly increased risk of VTE (P=0.04). Chemical prophylaxis showed a trend toward reduction in the risk of VTE (2.4{\%} vs. 9.1{\%}, P=0.13). The number of individual patient prothrombotic risk factors showed a trend towards increased risk of VTE (P=0.12). Conclusions The current rate of 4.1{\%} is at the lower end of the range of reported incidence for musculoskeletal oncology patients. Furthermore, VTE did not occur only in patients with hip/thigh sarcomas, as previously reported by some. The trend for reduced incidence with chemoprophylaxis favors prophylactic measures but requires further substantiation in larger studies.",
keywords = "bone sarcoma, chemoprophylaxis, deep venous thrombosis, pulmonary embolus, SCIP, soft-tissue sarcoma, thromboembolic disease, thromboprophylaxis, venous thromboembolism",
author = "Damron, {Timothy A.} and Zabi Wardak and Bradley Glodny and William Grant",
year = "2011",
month = "6",
day = "1",
doi = "10.1002/jso.21884",
language = "English (US)",
volume = "103",
pages = "643--647",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention

T2 - A report from prior to the initiation of SCIP measures

AU - Damron, Timothy A.

AU - Wardak, Zabi

AU - Glodny, Bradley

AU - Grant, William

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Background and Objectives This study reviews incidence and risk factors for venous thromboembolism (VTE) in bone/soft-tissue sarcoma patients prior to the initiation of Surgical Care Improvement Program (SCIP) measures in October 2009. Methods A retrospective chart review identified 171 cases of bone (51) and soft-tissue (120) sarcoma. Data were extracted on demographics, histology, presence of metastasis at presentation, type of adjuvant therapy, and established risk factors for VTE. Risk factors and outcomes were analyzed using chi-square and logistic regression with the Fisher exact test. Results The rate of clinically diagnosed VTE was 4.1% (7/171). Only those patients undergoing chemotherapy were found to have a significantly increased risk of VTE (P=0.04). Chemical prophylaxis showed a trend toward reduction in the risk of VTE (2.4% vs. 9.1%, P=0.13). The number of individual patient prothrombotic risk factors showed a trend towards increased risk of VTE (P=0.12). Conclusions The current rate of 4.1% is at the lower end of the range of reported incidence for musculoskeletal oncology patients. Furthermore, VTE did not occur only in patients with hip/thigh sarcomas, as previously reported by some. The trend for reduced incidence with chemoprophylaxis favors prophylactic measures but requires further substantiation in larger studies.

AB - Background and Objectives This study reviews incidence and risk factors for venous thromboembolism (VTE) in bone/soft-tissue sarcoma patients prior to the initiation of Surgical Care Improvement Program (SCIP) measures in October 2009. Methods A retrospective chart review identified 171 cases of bone (51) and soft-tissue (120) sarcoma. Data were extracted on demographics, histology, presence of metastasis at presentation, type of adjuvant therapy, and established risk factors for VTE. Risk factors and outcomes were analyzed using chi-square and logistic regression with the Fisher exact test. Results The rate of clinically diagnosed VTE was 4.1% (7/171). Only those patients undergoing chemotherapy were found to have a significantly increased risk of VTE (P=0.04). Chemical prophylaxis showed a trend toward reduction in the risk of VTE (2.4% vs. 9.1%, P=0.13). The number of individual patient prothrombotic risk factors showed a trend towards increased risk of VTE (P=0.12). Conclusions The current rate of 4.1% is at the lower end of the range of reported incidence for musculoskeletal oncology patients. Furthermore, VTE did not occur only in patients with hip/thigh sarcomas, as previously reported by some. The trend for reduced incidence with chemoprophylaxis favors prophylactic measures but requires further substantiation in larger studies.

KW - bone sarcoma

KW - chemoprophylaxis

KW - deep venous thrombosis

KW - pulmonary embolus

KW - SCIP

KW - soft-tissue sarcoma

KW - thromboembolic disease

KW - thromboprophylaxis

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=79955376338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955376338&partnerID=8YFLogxK

U2 - 10.1002/jso.21884

DO - 10.1002/jso.21884

M3 - Article

C2 - 21370234

AN - SCOPUS:79955376338

VL - 103

SP - 643

EP - 647

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 7

ER -